Related Experiment Video
Updated: Jan 20, 2026
Model of Ischemia and Reperfusion Injury in Rabbits
Published on: November 3, 2023
Cardioprotective mechanism of FTY720 in ischemia reperfusion injury
1The Aga Khan University, Medical College, Karachi, Pakistan, Phone: +92 21 3486 4465.
Abstract:
Cardioprotection is a very challenging area in the field of cardiovascular sciences. Myocardial damage accounts for nearly 50% of injury due to reperfusion, yet there is no effective strategy to prevent this to reduce the burden of heart failure. During last couple of decades, by combining genetic and bimolecular studies, many new drugs have been developed to treat hypertension, heart failure, and cancer. The use of percutaneous coronary intervention has reduced the mortality and morbidity of acute coronary syndrome dramatically. However, there is no standard therapy available that can mitigate cardiac reperfusion injury, which contributes to up to half of myocardial infarcts. Literature shows that the activation of sphingosine receptors, which are G protein-coupled receptors, induces cardioprotection both in vitro and in vivo. The exact mechanism of this protection is not clear yet. In this review, we discuss the mechanism of ischemia reperfusion injury and the role of the FDA-approved sphingosine 1 phosphate drug fingolimod in cardioprotection.
Insights
Sphingosine receptors activation shows promise for cardioprotection against myocardial damage from reperfusion injury. Further research into drugs like fingolimod could lead to new treatments for heart failure.
Area of Science:
- Cardiovascular Sciences
- Molecular Biology
- Pharmacology
Background:
- Myocardial damage from ischemia-reperfusion injury contributes significantly to heart failure.
- Current treatments for acute coronary syndrome do not mitigate reperfusion injury.
- Sphingosine receptor activation is linked to cardioprotection, but mechanisms remain unclear.
Purpose of the Study:
- To review the mechanisms of ischemia-reperfusion injury.
- To explore the potential cardioprotective role of sphingosine 1 phosphate (S1P) drugs, specifically fingolimod.
Main Methods:
- Literature review of genetic and biomolecular studies.
- Analysis of in vitro and in vivo data on sphingosine receptor activation.
- Discussion of fingolimod's mechanism in the context of cardioprotection.
Main Results:
- Ischemia-reperfusion injury causes substantial myocardial damage, contributing to heart failure.
- Sphingosine receptor activation demonstrates cardioprotective effects.
- The precise mechanisms underlying this protection require further elucidation.
Conclusions:
- Targeting sphingosine receptors may offer a novel strategy for cardioprotection.
- Fingolimod, an FDA-approved S1P drug, presents a potential therapeutic candidate for mitigating reperfusion injury.
- Further investigation is warranted to fully understand and leverage S1P-mediated cardioprotection.
Related Concept Videos
06:11Model of Ischemia and Reperfusion Injury in Rabbits
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
07:07Murine Model of Intestinal Ischemia-reperfusion Injury
07:23Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
09:09Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
07:37A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure